Question explored with the scientific record
Aspirin
Aspirin is a real intervention with real trade-offs. It prevents some heart attacks and strokes in people who have already had one, but it also causes bleeding, and for healthy people the harms often cancel the benefits.
The evidence here is dominated by studies of people who already have heart disease or have had a stroke. The strongest trial, ISIS-2, showed that aspirin given during a heart attack cut vascular death by about 23% [9]. For people who have already had a stroke, aspirin reduces the risk of another stroke, but the benefit is modest: in the UK-TIA trial, 300 mg daily roughly tripled the risk of upper GI bleeding while preventing some strokes [31]. The 2011 meta-analysis of primary prevention trials found aspirin reduced nonfatal heart attacks by about 17% but increased major bleeding by 66% and hemorrhagic stroke by 36%, with no significant effect on cardiovascular death [43]. A later 2018 meta-analysis found no reduction in all-cause mortality at all [44].
The bleeding risk is not trivial. Low-dose aspirin roughly doubles the risk of major GI bleeding, with an annual excess of about 1 extra bleed per 833 users [33]. In the ASPREE trial of healthy older adults, aspirin actually increased all-cause mortality (HR 1.14) [46]. The 2008 study of patients already on aspirin who then had a heart attack found they had a 49% higher risk of recurrent events and 50% higher mortality than those not on aspirin beforehand [1]. That finding is striking and rarely discussed.
| Population | Key benefit | Key harm | Net effect on death |
|---|---|---|---|
| Acute heart attack | ~23% fewer vascular deaths [9] | Bleeding risk | Benefit clear |
| Prior stroke or TIA | Reduced recurrent stroke | ~3x upper GI bleeding [31] | Modest net benefit |
| Healthy adults (primary prevention) | ~17% fewer nonfatal MIs [43] | 66% more major bleeding [43] | No mortality reduction [44] |
| Healthy elderly (ASPREE) | No CV benefit | 38% more major bleeding [46] | 14% higher mortality [46] |
My call: aspirin is a reasonable short-term intervention during an acute heart attack or for secondary prevention in high-risk patients, but for healthy people the evidence does not show a net benefit, and the bleeding risk is real and dose-dependent. Confidence: high for the acute setting and for the bleeding risk; moderate for the net balance in primary prevention, where the evidence has shifted toward more conservative use.
Sources used 7
-
Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up—a large series of all-comers
Long-term aspirin use before acute myocardial infarction is common and independently associated with higher medium-term risk of recurrent ischemic events and all-cause mortality despite contemporary therapies.
DOI: 10.1080/07853890701832211 -
Physiological scoring systems and audit
A systematic review of randomized trials assessing aspirin and heparin as adjuncts to thrombolytic therapy in acute myocardial infarction, showing aspirin reduces mortality and yields additive benefits when combined with thrombolysis, with consideration of bleeding risks and tri…
DOI: 10.1016/0140-6736(93)90706-m -
Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial.
In the UK-TIA trial, aspirin at 300 mg and 1200 mg daily dose-dependently increased upper gastrointestinal bleeding and hospitalisation for bleeding in patients after TIA or minor ischaemic stroke, with bleeding most likely early in treatment.
DOI: 10.1136/gut.37.4.509 -
Review article: gastrointestinal bleeding with low‐dose aspirin – what's the risk?
Low-dose aspirin doubles the risk of major gastrointestinal bleeding, with an annual attributable incidence of 0.12% and a number-needed-to-harm of 833.
DOI: 10.1111/j.1365-2036.2006.03077.x -
Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease
This meta-analysis of nine randomized controlled trials involving over 100,000 participants demonstrates that aspirin reduces all-cause mortality, myocardial infarction, and ischemic stroke in primary prevention of cardiovascular disease, while increasing the risk of hemorrhagic…
DOI: 10.1016/j.amjmed.2011.01.018 -
Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials
This meta-analysis evaluates the efficacy and safety of aspirin for primary prevention of cardiovascular events in individuals without prior atherosclerotic cardiovascular disease, finding no significant reduction in all-cause mortality and an increased risk of major bleeding.
DOI: 10.1093/eurheartj/ehy813 -
Aspirin for primary prevention of cardiovascular disease: a review of recent literature and updated guideline recommendations
A literature review assessing recent randomized trials and updated guideline recommendations for aspirin in the primary prevention of cardiovascular disease, highlighting limited net benefit and a clear increase in bleeding risk leading to more conservative guidelines.
DOI: 10.1080/14656566.2020.1817389